Lanreotide and diazoxide have comparable effects on glucose levels in an elderly Japanese insulinoma patient: a case report.
continuous glucose monitoring
diazoxide
elderly insulinoma
lanreotide
Journal
Journal of rural medicine : JRM
ISSN: 1880-487X
Titre abrégé: J Rural Med
Pays: Japan
ID NLM: 101274897
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
12
01
2021
accepted:
27
05
2021
entrez:
28
10
2021
pubmed:
29
10
2021
medline:
29
10
2021
Statut:
ppublish
Résumé
An insulinoma is a pancreatic neuroendocrine tumor that causes hypoglycemia. In the elderly, as surgery is not always possible, drugs are an important alternative. However, the effects of lanreotide on insulinomas have not yet been elucidated. We report the case of an 85-year-old Japanese woman who was admitted for loss of consciousness and hypoglycemia, which was resolved after intravenous glucose infusion. Insulin secretion was not inhibited during hypoglycemia. Enhanced computed tomography and OctreoScan scintigraphy revealed a pancreatic tumor (diameter, 13 mm) with radiotracer accumulation. Thus, clinical insulinoma was confirmed. However, the patient refused further examination and surgery. Diazoxide (150 mg/day) therapy resolved hypoglycemia but caused fluid retention. Consequently, we switched to lanreotide (120 mg/6 weeks). Continuous glucose monitoring revealed that both drugs had comparable effects on interstitial glucose normalization. Furthermore, 447 days after the initiation of lanreotide treatment, the patient had no hypoglycemic symptoms. Therefore, lanreotide may be a useful alternative treatment option for inoperable insulinomas in elderly individuals.
Identifiants
pubmed: 34707739
doi: 10.2185/jrm.2020-065
pii: 2020-065
pmc: PMC8527614
doi:
Types de publication
Journal Article
Langues
eng
Pagination
280-285Informations de copyright
©2021 The Japanese Association of Rural Medicine.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Exp Clin Endocrinol Diabetes. 2012 Feb;120(2):68-72
pubmed: 22187292
Acta Chir Belg. 2020 May 18;:1-4
pubmed: 32375590
Endocr J. 2019 Feb 28;66(2):149-155
pubmed: 30504655
J BUON. 2020 May-Jun;25(3):1302-1314
pubmed: 32862570
Intern Med. 2018 Dec 1;57(23):3407-3412
pubmed: 30101920
Clin Endocrinol (Oxf). 2008 Jun;68(6):912-8
pubmed: 18088393
Oncologist. 2017 Mar;22(3):272-285
pubmed: 28220021
J Gastroenterol. 2015 Jan;50(1):58-64
pubmed: 24499825
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Endocr J. 2006 Feb;53(1):79-85
pubmed: 16543676
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
J Clin Endocrinol Metab. 2018 Mar 23;:
pubmed: 29590371
Pol J Pathol. 2017;68(2):97-101
pubmed: 29025242
Endocr Relat Cancer. 2021 May;28(5):291-300
pubmed: 33729991
Clin Endocrinol (Oxf). 2019 Jun;90(6):798-804
pubmed: 30817011
J Clin Endocrinol Metab. 2009 Apr;94(4):1069-73
pubmed: 19141587
Endocrine. 2021 Feb;71(2):502-513
pubmed: 33052555
Eur J Endocrinol. 2005 May;152(5):757-67
pubmed: 15879362
Pancreas. 2010 May;39(4):544-6
pubmed: 20418760